Company intelligence / Profile preview

Kineta Inc.

Ownership: Public · KA
Employees: ~10
Development stage: Other

Overview

Kineta has developed a pipeline focused on next-generation immunotherapies targeting mechanisms of cancer immune resistance. Its lead asset, KVA12123—a VISTA-blocking antibody—is in Phase 1/2 clinical trials for advanced solid tumors. Early results from the VISTA101 trial show partial responses and stable disease with no dose-limiting toxicities observed. The company also has a preclinical anti-CD27 agonist mAb program. In early 2024, Kineta underwent significant restructuring due to funding shortfalls and began exploring strategic alternatives, including a pending acquisition by TuHURA Biosciences.

Therapeutic areas: Oncology
Modalities: Fully human monoclonal antibodies (mAbs)Checkpoint inhibitors
Industry: Biotech

Partnerships

No major pharma partnerships publicly disclosed as of latest updates.

Beyond the preview

Go deeper on Kineta Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kineta Inc..